GH therapy in PWS allows for increased stature, muscle mass, strength and physical activity, thereby improving metabolic rate and energy expenditure, resulting in decreased fat mass and obesity status, particularly when administered at a young age [4,14,15,16,17,18,19]. The gene discussed is GH1; the disease is obesity due to melanocortin 4 receptor deficiency.